Combining standard adjuvant chemotherapy with the immune checkpoint inhibitor atezolizumab [Tecentriq] leads to a significant improvement in disease-free survival in a subset of patients with Stage ...

Results from the Phase III SERENA-6 clinical trial found that switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for ...

A pre-surgical combination therapy including pembrolizumab [Keytruda] plus dabrafenib [Tafinlar] and trametinib [Mekinist] (DTP) significantly improved survival in patients with rare BRAF ...

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, ...

People who used GLP-1 receptor agonists, like Ozempic, had a modestly lower risk for obesity-related malignancies, especially colon and rectal cancer.

Chemotherapy doesn’t just kill cancer cells. It also affects the microbes in the digestive tract. Researchers at UC San Francisco have discovered that some gut bacteria can reduce the side effects of ...

On May 15, the Food and Drug Administration (FDA) approved Zynyz (retifanlimab) immunotherapy for people with advanced anal cancer based on promising results from a late-stage clinical trial. This ...

Welcoming participants to the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place this week Chicago, ASCO CEO Clifford Hudis, MD, acknowledged the detrimental effects of ...

Chemotherapy plus immunotherapy maintenance regimen extends progression-free and overall survival for patients with extensive-stage small-cell lung cancer.

Accurate classification of breast cancer receptor status can help guide treatment decisions, making more patients eligible for HER2 targeted therapies.

A s more of these latest cancer technologies do get approved for treatment, new approaches can bring new problems, experts say. For example, with radiotherapeutics, one big challenge is to source ...

About one in four young adults between the ages of 18 and 25 regularly use e-cigarettes to vape nicotine, as well as 7% of U.S. high school students. The growing popularity of vaping has reversed ...